Elotuzumab
- Generic Name
- Elotuzumab
- Brand Names
- Empliciti
- Drug Type
- Biotech
- CAS Number
- 915296-00-3
- Unique Ingredient Identifier
- 1351PE5UGS
- Background
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.
- Indication
Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
- Associated Conditions
- Refractory Multiple Myeloma
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
- Conditions
- Multiple Myeloma
- Interventions
- Procedure: Autologous Stem Cell Transplant (ASCT)Biological: Expanded Natural Killer (ENK) Cells
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT03003728
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT03000634
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 47
- Registration Number
- NCT02969837
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸NorthShore University Health System, Evanston, Illinois, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Early Patient Access Treatment Use Protocol CA204-220
- Conditions
- Multiple Myeloma
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT02856438
- Locations
- 🇯🇵
Local Institution, Osaka-shi, Osaka, Japan
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- Procedure: autologous stem cell transplantation
- First Posted Date
- 2016-07-25
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 53
- Registration Number
- NCT02843074
- Locations
- 🇺🇸
HCA Midwest Health/Research Medical Center, Kansas City, Missouri, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 67
- Registration Number
- NCT02719613
- Locations
- 🇺🇸
Local Institution - 0009, Atlanta, Georgia, United States
🇺🇸Local Institution - 0002, Boston, Massachusetts, United States
🇯🇵Local Institution - 0048, Koto-ku, Tokyo, Japan
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT02718833
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Newton-Wellesley Hospital, Newton, Massachusetts, United States
Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Hearn Jay Cho
- Target Recruit Count
- 15
- Registration Number
- NCT02655458
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 117
- Registration Number
- NCT02654132
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 74
- Registration Number
- NCT02612779
- Locations
- 🇺🇸
Bay Hematology Oncology, Easton, Maryland, United States
🇺🇸Southern Cancer Center, Mobile, Alabama, United States
🇺🇸Virginia Cancer Specialists (Leesburg) - USOR, Leesburg, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.